Imovax d.T. Adult

Diphtheria & tetanus vaccine (adsorbed): Purified diphtheria toxoid not less than 2 IU, purified tetanus toxoid not less than 20 IU

Active immunisation against tetanus & diphtheria in childn ≥7 yr & adults, in the following situations: As primary vaccination series in people not previously vaccinated against tetanus & diphtheria; to complete the primary vaccination series in people who did not complete it before 7 yr old; as a booster dose in cases where the primary vaccination series has already been completed; in case of wounds, as prophylaxis against tetanus & as booster dose against diphtheria.

IM Primary vaccination series 1st dose in the chosen date; 2nd dose: 1-2 mth after the 1st dose; 3rd dose: 6-12 mth after the 2nd dose. People who suffer from bleeding diathesis should be vaccinated by deep SC inj. Booster 0.5 mL single dose every 5-10 yr. Minor or clean wounds Vaccination is recommended in people who have not completed their primary vaccination series, when this is unknown, or when the immunisation status is uncertain, or >10 yr have passed since the last booster dose. When the person has completed his/her primary vaccination series against tetanus & has received his/her last booster dose in the last 10 yr, revaccination or use of anti-tetanus Ig is not recommended. Other types of wound eg, major & contaminated Vaccination will always be carried out, unless the person has completed his/her primary vaccination series against tetanus & has also received his/her last booster dose in the last 5 yr. In people who have not completed their primary vaccination series against tetanus, when this is unknown, or when the immunisation status is uncertain, anti-tetanus Ig should be administered in addition to the vaccine.

Hypersensitivity. Postpone during the course of febrile or acute infection processes & in people, who due to a history of exposure, could be in the incubation period of an infection other than the diphtheria or tetanus, which is known, or suspected to be susceptible. History of thrombocytopenia, hypersensitivity reactions or neurological complications after prior vaccination against tetanus &/or diphtheria. If there is any contraindication for diphtheria vaccine administration, only the tetanus vaccine should be administered. When complications eg, allergic reactions & central &/or peripheral nervous system complications are present, consider the vaccination risk against the risk of getting tetanus & diphtheria. In the cases of wounds in immunocompromised subjects, only the tetanus vaccine should be administered, & it should not be accompanied by the diphtheria component. In case of wounds, & when there is an absolute contraindication, anti-tetanus Ig should be administered (2 x 250 IU at 4-wk intervals).

Do not administer by intravascular inj or intradermally. Immunosuppressive therapy or immunodeficiency. Guillain-Barré syndrome or brachial neuritis. To prevent hypersensitivity reactions, avoid the inj during the first 5 yr after vaccination, both in people who have completed a primary vaccination series or in those who have received a booster dose. Pregnant women not immunised or insufficiently immunised may be vaccinated during the 2nd & 3rd trimester of pregnancy, especially if travelling to countries w/ endemic diphtheria or suspected exposure.

Very rare: Lymphadenopathy; type I hypersensitivity reactions/anaphylactic reaction; headache, discomfort; hypotension (w/in the context of type I hypersensitivity reactions); allergy-like symptoms eg, generalized pruritus, urticaria or oedema; facial oedema, angioedema, Quincke's disease; myalgia, arthralgia; inj site reactions eg, pain, erythema, induration or oedema.

Vaccines, Antisera & Immunologicals

J07AM51 - tetanus toxoid, combinations with diphtheria toxoid ; Belongs to the class of tetanus bacterial vaccines.

P₁S₁S₃